SS-31

★ 70

SS-31 / Elamipretide (Bendavia)

Mitochondria-protective peptide

Longevity

Half-life

~2-3 hours (SubQ)

Route

Subcutaneous (SubQ)

Cycle

8-16 week cycles,

Status

Phase 3 (Stealth BioTherapeutics)

About

A small peptide that binds the inner mitochondrial membrane and reduces cardiolipin oxidation. Phase 3 trials in primary mitochondrial myopathy and heart failure.

Mechanism

Binds cardiolipin in the inner mitochondrial membrane, protects the electron transport chain, reduces ROS.

Dosage

beginner

Amount: 20 mg
Frequency: 1x per day
Route: Subcutaneous (SubQ)
Duration: 4-8 weeks

standard

Amount: 40 mg
Frequency: 1x per day
Route: Subcutaneous (SubQ)
Duration: 8-12 weeks

advanced

Amount: 60 mg
Frequency: 1x per day
Route: Subcutaneous (SubQ)
Duration: 12-16 weeks

Timing

Best in the morning — energy-related effects.

Cycle structure

8-16 week cycles, with a 4-week break.

Reconstitution & Storage

100 mg + 2 mL → 50 mg/mL

Larger vials require larger bac volumes due to mg quantity.

Lyophilized: refrigerated. Reconstituted: 2-8°C, 30 days.

Benefits

• Protects mitochondria
• Improved energy and endurance
• Cardioprotective effects
• Possibly anti-aging via mitochondrial biogenesis
• Reduced muscle fatigue

Side effects

• Injection-site irritation
• Rare: headache
• Well tolerated in clinical trials

Contraindications

• Limited pregnancy data
• Drug interactions not yet fully studied

Gender notes

Men

Same dose as general protocol.

Women

Same dose.

Research

Karaa et al: SS-31 in mitochondrial myopathy ↗
MMPOWER-3 trial in primary mitochondrial myopathy.

Neurology · 2020

Stacks well with

MOTS-C EPITALON

Track SS-31 doses in the app

Built-in reconstitution calculator, dose log, and reminders. Free on Android.

Get on Google Play

Educational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.